| Literature DB >> 33512409 |
Niloufer Khan1, Sarah Lindner2, Antonio L C Gomes2, Sean M Devlin3, Gunjan L Shah1,4, Anthony D Sung5, Craig S Sauter1,4, Heather J Landau1,4, Parastoo B Dahi1,4, Miguel-Angel Perales1,4, David J Chung1,4, Alexander M Lesokhin4,6, Anqi Dai2, Annelie Clurman1, John B Slingerland1, Ann E Slingerland1, Daniel G Brereton1, Paul A Giardina1, Molly Maloy1, Gabriel K Armijo2, Carlos Rondon-Clavo1, Emily Fontana2, Lauren Bohannon5, Sendhilnathan Ramalingam5, Amy T Bush5, Meagan V Lew5, Julia A Messina7, Eric Littmann8, Ying Taur4,9, Robert R Jenq10, Nelson J Chao5, Sergio Giralt1,4, Kate A Markey1,4, Eric G Pamer8, Marcel R M van den Brink1,2,4, Jonathan U Peled1,4.
Abstract
We previously described clinically relevant reductions in fecal microbiota diversity in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Recipients of high-dose chemotherapy and autologous HCT (auto-HCT) incur similar antibiotic exposures and nutritional alterations. To characterize the fecal microbiota in the auto-HCT population, we analyzed 1161 fecal samples collected from 534 adult recipients of auto-HCT for lymphoma, myeloma, and amyloidosis in an observational study conducted at 2 transplantation centers in the United States. By using 16S ribosomal gene sequencing, we assessed fecal microbiota composition and diversity, as measured by the inverse Simpson index. At both centers, the diversity of early pretransplant fecal microbiota was lower in patients than in healthy controls and decreased further during the course of transplantation. Loss of diversity and domination by specific bacterial taxa occurred during auto-HCT in patterns similar to those with allo-HCT. Above-median fecal intestinal diversity in the periengraftment period was associated with decreased risk of death or progression (progression-free survival hazard ratio, 0.46; 95% confidence interval, 0.26-0.82; P = .008), adjusting for disease and disease status. This suggests that further investigation into the health of the intestinal microbiota in auto-HCT patients and posttransplant outcomes should be undertaken.Entities:
Mesh:
Year: 2021 PMID: 33512409 PMCID: PMC7976512 DOI: 10.1182/blood.2020006923
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 25.476